High eIF4E, VEGF, and microvessel density in stage I to III breast cancer

Annals of Surgery

Volumn 243, Issue 5, 2006, Pages 684-691

  Byrnes, Kerry ^a   White, Stephen ^a   Chu, Quyen ^a   Meschonat, Carol ^a   Yu, Herbert ^d   Johnson, Lester W ^c   DeBenedetti, Arrigo ^b   Abreo, Fleurette ^b   Turnage, Richard H ^a   McDonald, John C ^a   Li, Benjamin D ^a,b  

^a Louisiana State University School of Medicine Shreveport   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c EA Conway Hospital   (United States)

^d YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4E; MESSENGER RNA; VASCULOTROPIN; VASCULOTROPIN A;

ADULT; ARTICLE; BREAST CANCER; CANCER STAGING; CAPILLARY DENSITY; CLINICAL PROTOCOL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC VALUE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; TRANSLATION INITIATION; TUMOR VASCULARIZATION; UNTRANSLATED REGION; BIOSYNTHESIS; BREAST TUMOR; CHEMISTRY; FEMALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; VASCULARIZATION;

BREAST NEOPLASMS; EUKARYOTIC INITIATION FACTOR-4E; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33746206552     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000216770.23642.d8     Document Type: Article

References (31)

1. Jemal A, Murray T, Ward E, et al. Cancer Statistics 2005. CA Cancer J Clin. 2005;55:10-30.
2. Weidner N, Cady B, Goodson WH III. Pathologic prognostic factors for patients with breast carcinoma: which factors are important. Surg Oncol Clin North Am. 1997;6:415-453.
3. Jatoi I, Hilsenbeck SG, Clark GM, et al. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol. 1999;17:2334-2340.
4. DeBenedetti A, Harris AL. EIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol. 1999;31:59-72.
5. Rhoads RE, Joshi-Barve S, Rinker-Schaeffer C. Mechanism of action and regulation of protein synthesis initiation factor 4E: effects of mRNA discrimination, cellular growth rate, and oncogenesis. Prog Nucleic Acid Res Mol Biol. 1993;46:183-219.
6. Rosenwald IB, Lazaris-Karatzas A, Sonenberg N, et al. Elevated levels of Cyclin D1 in response to increased expression of Eukaryotic Initiation Factor 4E. Mol Cell Biol. 1993;13:7358.
7. Li Y, DeFatta R, Anthony C, et al. A translationally regulated Tousled Kinase phosphorylates histone H3 and confers radioresistance when overexpressed. Oncogene. 2001;20:726.
8. Kevil C, DeBenedetti A, Payne DK, et al. Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis. Int J Cancer. 1996;65:786.
9. Kevil C, Carter P, Hu B, et al. Translational enhancement of FGF-2 by eIF-4 factors, and alternate utilization of CUG and AUG codons for translation initiation. Oncogene. 1995;11:2339-2348.
10. DeBenedetti A, Joshi-Barve S, Rinker-Schaeffer C, et al. Expression of antisense RNA against initiation factor eIF4E mRNA in HeLa cells results in lengthened cell division times, diminished translation rates, and reduced levels of both eIF4E and p220 component of eIF4F. Mol Cell Biol. 1991;11:5435.
11. DeBenedetti A, Rhoads RE. Overexpression of eukaryotic protein synthesis initiation factor 4E in HeLa Cells results in aberrant growth and morphology. Proc Natl Acad Sci USA. 1990;87:8212.
12. DeBennedetti A, Joshi B, Graff JR, et al. CHO cells transformed by the translation factor eIF-4E display increased c-myc expression, but requires overexpression of max for tumorigenicity. Mol Cell Diff. 1994;2:347.
13. Zhu N, Gu L, Findley H, et al. Transcriptional repression of the Eukaryotic Initiation Factor 4E gene by wild type p53. Biochem Biophys Res Commun. 2005;335:1272-1279.
14. Kerekatte V, Smiley K, Hu B, et al. The proto-oncogene/translation factor eIF4E: a survey of its expression in breast carcinomas. Int J Cancer. 1995;64:27.
15. Vazquez SH, Byrnes K, Chu Q, et al. Eukaryotic Factor 4E (eIF4E) expression in malignant versus inflammatory colon tissue. Ann Surg Oncol. 2005;12(suppl):90-91.
16. Nathan CO, Liu L, Li BDL, et al. Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer. Oncogene. 1997;15:579.
17. Chu QD, Turnage R, McClusky D, et al. Overexpression of Eukaryotic Initiation Factor 4E (eIF4E) in soft tissue neoplasms. Proceedings of the AACR. 2004;45:4285.
18. Li BDL, McDonald JC, Nassar R, et al. Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression. Ann Surg. 1998;227:756-763.
19. Li BDL, Gruner JS, Abreo F, et al. Prospective study of Eukaryotic Initiation Factor 4E protein elevation and breast cancer outcome. Ann Surg. 2002;235:732-739.
20. McClusky D, Chu Q, Yu H, et al. A prospective trial on Initiation Factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer. Ann Surg. 2005;242:584-592.
21. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1989;82:4-6.
22. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671-674.
23. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
24. Gimbrone M, Leapman S, Cotran R, et al. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med. 1972;136:261-276.
25. Linderholm B, Lindh B, Tavelin B, et al. p53 and Vascular-Endothelial- Growth-Factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int J Cancer. 2000;89:51-62.
26. Gasparini G. Prognostic value of Vascular Endothelial Growth Factor in breast cancer. Oncologist. 2000;10:37-44.
27. Jennbacken K, Valbo C, Wang W, et al. Expression of Vascular Endothelial Growth Factor C (VEGF-C) and VEGF Receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate. 2005;65:110-116.
28. Benoy I, Salgado R, Elst H, et al. Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer. Breast Cancer Res. 2005;7:R210-R219.
29. AJCC Staging Manual, 6th ed. Springer-Verlag, 2002.
30. Braun S, Pantel K, Muller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, of III breast cancer. N Engl J Med. 2000;342:525-533.
31. Weidner N, Semple J, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.